Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Alizyme Acquires Patent And Intellectual Property

Posted on: 18 Mar 05

® colonic drug delivery technology owned by  BTG plc (LSE:BGC).


COLAL® is a drug delivery technology which enables drugs to be taken orally and then be specifically released when the preparation reaches the colon. The technology is currently being exploited in the development of COLAL-PRED®, Alizyme’s novel product for the treatment of ulcerative colitis, which recently received approval for a pivotal Phase III clinical trial in


The patents are currently granted in the major commercial territories, including the ® and with other potential products in the future.


In respect of those patents that relate to the COLAL® drug delivery technology that cover Alizyme’s COLAL-PRED® product, the terms of the deal provide that Alizyme pays £750,000 on signature of the agreement and a further £550,000 on recording the assignments at the appropriate patent offices. Alizyme will take outright ownership of these patents, with no further amounts being payable.


In respect of the other assigned patent families, which relate to other aspects of colonic drug delivery technology, Alizyme will pay a total of £75,000 over the next three years, royalties on any sales of relevant products and a share of any other consideration received by Alizyme for exploitation of these patents. Alizyme will look to identify new potential product opportunities in conjunction with this drug delivery technology.



Commenting, Dr Richard Palmer, Chief Executive Officer said:


“We are pleased to have acquired this intellectual property estate. This transaction is in line with our policy of owning, where possible, the intellectual property supporting our existing products, to give us flexibility indeveloping new products and in leveraging the maximum commercial value from our portfolio.”



For further information, please contact:

Dr Richard Palmer, Chief Executive Officer


Tim McCarthy, Finance Director



+44 (0) 1223 896000



Lisa Baderoon/Rebecca Skye Dietrich



+44 (0) 20 7466 5000

Further information on Alizyme can be found on the Company’s website:


Editor’s Note

Alizyme plc

Alizyme is a speciality pharmaceutical development company, based in Ò, includes renzapride (completed Phase II for irritable bowel syndrome), ATL-962 (completed Phase IIb in obese patients and currently in a Phase IIb trial in obese diabetic patients), and ATL-104 (in a Phase IIa trial for mucositis).



COLAL® is a drug delivery technology which enables drugs to be taken orally and then be specifically released when the preparation reaches the colon. Achieving colonic release with conventional oral dosage forms has proved difficult because of the variation between individuals in transit times and conditions within the gastrointestinal tract. COLAL® overcomes this difficulty by covering small pellets containing the drug with a coating of ethylcellulose and a specific form of amylose (derived from starch). This coating prevents drug release in the stomach and small intestine. When the pellets reach the colon the amylose in the coating is broken down by bacterial enzymes and the drug is released.

(Note: COLAL® and COLAL-PRED® are registered trademarks of Alizyme Therapeutics Limited)

The identification of compounds for successful research, their progress through development and the obtaining of regulatory approvals or authorisations before marketing, manufacture and/or distribution of products is not certain or a formality. 

For more information:

Editor's Details

Dr Richard Palmer, Chief Executive
+44 (0) 20 7466 5000

Last updated on: 27/08/2010

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.